Lisata Therapeutics Agrees to $4.00 Per Share Acquisition by Kuva Labs in 85% Premium Deal
Key Insights
Lisata Therapeutics has entered a binding term sheet to be acquired by Kuva Labs (search) for $4.00 per share in cash, representing an 85% premium over the most recent closing price.
Stockholders will receive two additional contingent value rights worth $1.00 each, tied to certepetide milestone achievements including rights reversion from Qilu Pharmaceutical (search) and NDA filing.
The acquisition reflects the strategic value of Lisata's clinical pipeline, particularly certepetide, which Kuva previously licensed for use with its NanoMark MR imaging platform technology.
Lisata Therapeutics has entered into a binding term sheet to be acquired by privately-held Kuva Labs (search) for $4.00 per share in cash, representing an approximate 85% premium over the company's most recent closing stock price. The transaction, unanimously approved by both companies' boards of directors, includes additional contingent value rights that could bring the total premium to approximately 180%.
Under the agreement, Lisata stockholders will receive two non-tradeable contingent value rights (CVRs) valued at $1.00 per share each. The first CVR will be payable within 12 months of when rights to certepetide in the Greater China region revert to Lisata from Qilu Pharmaceutical (search). The second CVR will be triggered upon the filing of an NDA or similar registration document by Kuva for approval to commercialize certepetide in any indication in any jurisdiction.
Strategic Rationale Behind the Acquisition
The acquisition reflects the strategic value of Lisata's clinical pipeline and the breakthrough potential of its lead product candidate, certepetide. In November 2024, Kuva had already licensed Lisata's iRGD cyclic peptide product candidate for use with Kuva's NanoMark platform technology, beginning development of a potentially new class of advanced magnetic resonance imaging agents for solid tumor detection.
Kuva Labs (search), founded in 2019, is developing the proprietary NanoMark direct MR imaging platform that enables selective and unambiguous imaging of solid tumors (search) with high contrast and spatial resolution without ionizing radiation. The company's founders were motivated by tragic losses in cancer cases that could have benefited from better diagnostic tools.
Certepetide's Clinical Development Program
Certepetide, formerly known as LSTA1, is an investigational cyclic peptide designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate solid tumors (search) more effectively. The drug actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in tumors.
The compound has demonstrated the ability to modify the tumor microenvironment, making tumors more susceptible to immunotherapies. Lisata and its collaborators have generated significant non-clinical data demonstrating enhanced delivery of various emerging anti-cancer therapies, including immunotherapies and RNA-based therapeutics.
Regulatory Recognition and Clinical Progress
Certepetide has received substantial regulatory recognition, including Fast Track designation in the United States and Orphan Drug Designation for pancreatic cancer (search) in both the U.S. and European Union. The drug has also received Orphan Drug Designation for glioma (search) and osteosarcoma (search) in the United States, along with Rare Pediatric Disease Designation for osteosarcoma.
The company is currently conducting multiple Phase 2 trials across various indications. The ASCEND Phase 2b study is evaluating certepetide with gemcitabine/nab-paclitaxel in untreated metastatic pancreatic cancer (search) across 25 sites in Australia and New Zealand, with final results expected in Q1 2026. The BOLSTER Phase 2a study in cholangiocarcinoma (search) completed enrollment six months ahead of schedule, with topline data expected in Q4 2025.
Financial Position and Transaction Timeline
Lisata reported a cash position of $19.0 million as of September 30, 2025, with funding expected to support operations into early 2027. The company has no debt and narrowed its net loss to $4.2 million in Q3 2025 from $4.9 million in the prior year period.
The companies expect to enter into a definitive purchase agreement prior to February 27, 2026. Kuva will commence a tender offer to purchase all outstanding shares of Lisata common stock following execution of the definitive agreement.
Strategic Partnerships Strengthen Pipeline Value
Beyond the Kuva relationship, Lisata has established additional strategic partnerships that enhance the value of its CendR Platform technology. The company signed a nonexclusive license agreement with Catalent, granting global rights to evaluate certepetide as a SMARTag ADC payload. Preclinical data presented at the World ADC conference demonstrated improved efficacy and broader tumor penetration.
Lisata also formed a strategic alliance with GATC Health (search), leveraging AI-powered drug discovery to identify new indications and combination therapies for certepetide. These partnerships demonstrate the broad applicability of certepetide's mechanism of action across multiple therapeutic modalities.